Thailand presents ‘The New Thailand’ vision at ITB Berlin 2026
Healing-led luxury, sustainable routes and hidden gems advance Thailand's world-class positioning in…
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease
March 01, 2026 09:45 ET | Source: Celldex Therapeutics, Inc. - Late…
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical…
CGTN AMERICA & CCTV UN: CMG Presents “Prelude to the Spring Festival Gala” in New York City, Celebrating the Year of the Horse
WASHINGTON, Feb. 12, 2026 /PRNewswire/ -- CGTN America & CCTV UN releases…
HABANOS, S.A. PRESENTS TRINIDAD CORCEL: AN EXCLUSIVE VITOLA TO CELEBRATE THE CHINESE NEW YEAR
Habanos, S.A. presents Trinidad Corcel, the latest addition to the Trinidad brand's…
Castrol proudly presents: Drive Me To The Moon
Castrol unveils a new documentary in collaboration with Lunar Outpost: a worldwide…
ASUS Republic of Gamers Presents Next-Gen Gaming Innovations, Commemorates 20 Years of Gaming Excellence at CES 2026
KEY POINTS Two decades of gaming leadership: At its Dare to Innovate…
Samsung Presents ‘Your Companion to AI Living’ at The First Look during CES 2026
Next-generation AI-powered devices and experiences to be showcased at the company's exclusive…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
